gfp,
SPPI has EOquin in Phase III for bladder cancer. It hopes to have Ozarelix in Phase III for BPH by the end of this year. They have Isovorin approved, but I don't know the market for it at all. And they have the generic deal with GSK for Imitrex that should start bringing in revenue in about a year. Then they just in-licensed a third-generation taxane that is in Phase II. Then there is the arbitration with GPCB. And, of course, there is still Satraplatin (due to report OS numbers before the end of this year), but the consensus on Dew's board is that the drug will never be able to show statistical significance in prostate cancer. They have $70 million in cash and a market cap of around $125 million. So the enterprise value (EV) is approximately $55 million. Outside of IDIX, I don't know where you could find better value in micro-cap biotech.
Bladerunner
Market Data 
Markets 
AI
